为解决依维莫司治疗乳腺癌疗效受限问题，研究人员开展褪黑素联合依维莫司治疗激素受体阳性乳腺癌的研究。结果显示联合用药可抑制 mTOR 通路、促进凋亡等，表明褪黑素或可作乳腺癌治疗佐剂，提升依维莫司疗效。

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted ...

New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

How cancer cells adapt to maximise their ability to generate enough energy to survive and multiply could point scientists to ...

We are investigating the mechanisms by which cancer mutations deregulate the normal processes of cellular function and growth ...

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Novel cancer therapy combining multi-hydroxylated fullerene (MF) nanoparticles and mTOR inhibitors triggers organelle cascade ...